KORELASI ANTARA USIA DENGAN EKSPRESI BCL-2 PADA PASIEN KARSINOMA NASOFARING WHO TIPE III
DOI:
https://doi.org/10.29303/jku.v6i3.1.290Kata Kunci:
Usia, Bcl-2, Imunohistokimia, Karsinoma Nasofaring WHO tipe IIIAbstrak
Latar Belakang: Karsinoma nasofaring adalah karsinoma pada mukosa nasofaring dan paling banyak terjadi pada usia 40-49 tahun. Kegagalan apoptosis merupakan mekanisme dasar terjadinya karsinoma tersebut. Salah satu faktor yang berkaitan dengan abnormalitas apoptosis yang terjadi pada karsinoma nasofaring adalah Bcl-2
Tujuan: Mengetahui korelasi antara usia dengan ekspresi Bcl-2 pada pasien Karsinoma Nasofaring WHO tipe III
Metode: Penelitian ini merupakan penelitian deskriptif analitik dengan design cross sectional. Penelitian ini menggunakan data rekam medik pasien karsinoma nasofaring WHO tipe III dari Rumah Sakit Umum Provinsi NTB dan hasil pemeriksaan laboratorium yang mendeteksi ekspresi Bcl-2 pada blok paraffin pasien tersebut. Usia pasien dikategorikan menjadi <45 tahun dan ≥45 tahun. Pemeriksaan imunohistokimia pada penelitian ini mengelompokkan hasil ekspresi Bcl-2 menjadi 4 kategori (ekspresi Bcl-2 negatif, positif 1, positif 2, dan positif 3). Sampel penelitian ini ditentukan dengan teknik consecutive sampling. Data dianalisis dengan uji korelasi lambda.
Hasil: Pasien karsinoma nasofaring WHO tipe III di Rumah Sakit Umum Provinsi NTB yang berusia <45 tahun 26 pasien dan yang berusia ≥45 tahun 18 pasien. Hasil pemeriksaan imunohistokimia, dari 44 sampel yang diteliti, 15 orang mengekspresikan Bcl-2 negatif, 13 orang mengekspresikan Bcl-2 positif 1, 1 orang mengekspresikan Bcl-2 positif 2, dan 15 orang mengekspresikan Bcl-2 positif 3. Hasil uji korelasi lambda menunjukkan bahwa tidak terdapat korelasi yang signifikan antara usia dengan ekspresi Bcl-2 pada pasien karsinoma nasofaring WHO tipe III (p = 0,562).
Kesimpulan: Tidak terdapat korelasi yang signifikan antara usia dengan ekspresi Bcl-2 pada pasien Karsinoma Nasofaring WHO tipe III di Rumah Sakit Umum Provinsi NTB
Referensi
2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F.. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide. International Agency for Research on Cancer. 2012. Available from: http://globocan.iarc.fr [Accessed 12 September 2016].
3. Forman D, Bray F, Brewster DH, Mbalawa CG, Kohler B, Piñeros M, et al. Cancer Incidence in Five Continents [Internet]. Vol. X, World Health Organization. Lyon: International Agency for Research on Cancer; 2014. 954-958 p. Available from: http://www.iarc.fr/en/publications/pdfs-online/epi/sp164/ [Accessed 12 September 2016]
4. Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, et al. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer [Internet]. 2012 Apr 5;31(4):185–96. Available from: http://www.cjcsysu.cn/abstract.asp?fr=doi&idno=18043 [Accessed 7 September 2016]
5. Willis S, Day CL, Hinds MG, S DC, Huang DCS. The Bcl-2-regulated apoptotic pathway The Bcl-2-regulated apoptotic pathway. J Cell Sci. 2003; 4053–6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12972498 [Accessed 17 September 2016]
6. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol [Internet]. 2008;9(1):47–59. Available from: http://www.nature.com.gate1.inist.fr/nrm/journal/v9/n1/full/nrm2308.html%5Cnhttp://www.nature.com.gate1.inist.fr/nrm/journal/v9/n1/pdf/nrm2308.pdf [Accessed 12 September 2016]
7. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene. 2008;27(50):6398–406. Available from: http://www.nature.com/onc/journal/v27/n50/full/onc2008307a.html [Accessed 7 November 2016]
8. Dahlan MS, Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan. Edisi 3. 2013. Jakarta: Salemba Medika
9. Bray F, Ren J-S, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer [Internet]. 2013 Mar 1;132(5):1133–45. Available from: http://doi.wiley.com/10.1002/ijc.27711 [Accessed 12 September 2016]
10. Yu Y, Dong W, Li X, Yu E, Zhou X, Li S. Significance of c-Myc and Bcl-2 protein expression in nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg [Internet]. 2003;129(12):1322–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14676159 [Accessed 21 Oktober 2016]
11. Vera-Sempere FJ, Burgos JS, Botella MS, Morera C. Immunohistochemical expression of Bcl-2 oncoprotein in EBV-associated nasopharyngeal carcinoma correlated to histological type and survival. Histol Histopathol [Internet]. 1997;12(1):9–18. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9046038 [Accessed 23 Oktober 2016]
12. Fendri A, Kontos CK, Khabir A, Mokdad-Gargouri R, Ardavanis A, Scorilas A. Quantitative analysis of BCL2 mRNA expression in nasopharyngeal carcinoma: an unfavorable and independent prognostic factor. Tumour Biol. 2010;31(5):391–9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20514538 [Accessed 17 September 2016]
13. Chen M-K, Yang S-F, Lai J-C, Yeh K-T, Yang J-S, Chen L-S, et al. Expression of bcl-2 correlates with poor prognosis and modulates migration of nasopharyngeal carcinoma cells. Clin Chim Acta [Internet]. 2010;411(5–6):400–5. Available from: http://dx.doi.org/10.1016/j.cca.2009.12.010 [Accessed 7 September 2016]
14. Khabir A, Ghorbel A, Daoud J, Frikha M, Drira MM, Laplanche A, et al. Similar BCL-X but different BCL-2 levels in the two age groups of north African nasopharyngeal carcinomas. Cancer Detect Prev. 2003;27(4):250–5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12893071 [Accessed 20 Oktober 2016]
15. Yip KW, Shi W, Pintilie M, Martin JD, Mocanu JD, Wong D, et al. Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin Cancer Res. 2006;12(19):5726–32. . Available from: https://www.ncbi.nlm.nih.gov/pubmed/17020977 [Accessed 17 September 2016]
16. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science (80- ) [Internet]. 1985;228(4706):1440–3. Available from: http://www.sciencemag.org/cgi/doi/10.1126/science.3874430 [Accessed 13 September 2016]
17. Galteland E, Sivertsen E a, Svendsrud DH, Smedshammer L, Kresse SH, Meza-Zepeda L a, et al. Translocation t(14;18) and gain of chromosome 18/BCL2: effects on BCL2 expression and apoptosis in B-cell non-Hodgkin’s lymphomas. Leukemia [Internet]. 2005;19(12):2313–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16193090 [Accessed 11 September 2016]
18. Liu Y, Hernandez AM, Shibata D, Cortopassi GA. BCL2 translocation frequency rises with age in humans. Proc Natl Acad Sci U S A [Internet]. 1994;91(19):8910–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8090743%5Cnhttp://www.pnas.org/content/91/19/8910.full.pdf [Accessed 9 September 2016]
19. Chen M-K, Lai J-C, Chang C-C, Chang JH, Chang Y-J, Chen H-C. Prognostic impact of bcl-2 expression on advanced nasopharyngeal carcinoma. Head Neck [Internet]. 2008 Aug;30(8):1052–7. Available from: http://doi.wiley.com/10.1002/hed.20839 [Accessed 9 September 2016]
20. Damayanti BS, Hassan AH, Hernowo BS. Bcl-2 Immunoexpression as Radiotherapy Response Predictor in Undifferentiated Nasopharynx Carcinoma. 2015;1(1):1–13. Available from: http://jmh.maranatha.edu/index.php/jmh/article/view/8 [Accessed 20 Desember 2016].
